Results 101 to 110 of about 4,786 (145)

In vitro and in vivo Activity of 1-O-Hexadecylpropane-Diol-3-Phospho-Ganciclovir and 1-O-Hexadecylpropanediol-3-Phospho-Penciclovir in Cytomegalovirus and Herpes Simplex Virus Infections [PDF]

, 2001
Karl Y. Hostetler, Rachel J. Rybak, James R. Beadle, Michael F. Gardner, Kathy A. Aldern, Kristine N. Wright, Earl R. Kern   +6 more
openalex   +1 more source

LONG-TERM ORAL GANCICLOVIR PROPHYLAXIS FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN CYTOMEGALOVIRUS HIGH-RISK RENAL TRANSPLANT RECIPIENTS

, 2000
Josef Kletzmayr, Evelyn Kreuzwieser, Thomas Watkins‐Riedel, Gabriela Berlakovich, Josef Kovařík, Renate Klauser   +5 more
openalex   +1 more source

EMERGENCE OF CLINICALLY SIGNIFICANT GANCICLOVIR (GCV)- RESISTANT STRAINS OF CMV IN SOLID ORGAN TRANSPLANT RECIPIENTS.

, 2000
Carlos M. Isada, Belinda Yen‐Lieberman, Debra Kohn, Sherif B. Mossad, Stuart M. Flechner, Steven D. Mawhorter, Alan Taege, Steven M. Gordon, Janet Maurer, Steven Schmitt, Morton Goldman, David L. Longworth, Robin K. Avery   +12 more
openalex   +1 more source

LONG-TERM OUTCOMES IN HEART TRANSPLANT RECIPIENTS WHO RECEIVED GANCICLOVIR PROPHYLAXIS: IMPACT OF CMV AND CMV SEROSTATUS ON REJECTION, ALLOGRAFT VASCULOPATHY, AND SURVIVAL.

, 2000
Robin K. Avery, Sherif B. Mossad, James B. Young, Marlene Goormastic, Randall C. Starling, Kathy Hoercher, Robert E. Hobbs, David Pelegrin, Steven D. Mawhorter, Patrick M. McCarthy   +9 more
openalex   +1 more source

DEVELOPMENT OF CYTOMEGALOVIRUS RESISTANCE TO GANCICLOVIR AFTER ORAL MAINTENANCE TREATMENT IN A RENAL TRANSPLANT RECIPIENT

, 2000
Boris Bienvenu, É. Thervet, J Bedrossian, Catherine Scieux, M.C. Mazeron, D Thouvenot, C. Legendre   +6 more
openalex   +1 more source

DOSING OF INTRAVENOUS GANCICLOVIR FOR THE PROPHYLAXIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS1

, 2000
Jay A. Fishman, Maureen Doran, S A Volpicelli, A. Benedict Cosimi, James G. Flood, Robert H. Rubin   +5 more
openalex   +1 more source

PID13: COST-EFFECTIVENESS OF GANCICLOVIR IN PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER LIVER TRANSPLANTATION: A BAYESIAN APPROACH

, 2000
DJ Vanness, W. Ray Kim
openalex   +1 more source

Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo

, 2001
Chaysavanh Manichanh, Camille Olivier-Aubron, Jean‐Pierre Lagarde, Jean‐Thierry Aubin, Phillipe Bossi, Agnès Gautheret‐Dejean, Jean‐Marie Huraux, Henri Agut   +7 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ganciclovir Hepatotoxicity

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1987
A 33‐year‐old male with acquired immunodeficiency syndrome received ganciclovir for presumed cytomegalovirus retinitis. Although results of baseline liver function tests were abnormal, marked elevations of transaminases and alkaline phosphatase occurred when the drug was first instituted, as well as after rechallenge.
B F, Shea, S, Hoffman, G P, Sesin, S M, Hammer   +3 more
openaire   +2 more sources

Acyclovir and Ganciclovir

Pediatrics In Review, 2005
1. Elisabeth H. Villavicencio, MD, PhD 2. Gregg Talente, MD, MS 1. Brody School of Medicine at East Carolina University Greenville NC Antiviral Therapy for Varicella and Herpes Zoster. Arvin AM. Semin Pediatr Infect Dis. 2002;13 :12– 21[OpenUrl][1][CrossRef][2][PubMed][3] Oral Ganciclovir in Children: Pharmacokinetics, Safety, Tolerance ...
Gregg Talente, Elisabeth H. Villavicencio   +1 more
openaire   +2 more sources